Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
BS-1053 A Prospective Randomized Multi-Centered Safety and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures
This is a multi-centered, randomized trial in patients receiving lung biopsies. Patients will be randomized to either receive or not receive a Bio-Seal Biopsy Track Plug after a lung biopsy per standard hospital protocol. This study is designed to demonstrate safety and efficacy of the Bio-Seal Biopsy Track Plug in reducing pneumothorax rates post lung biopsy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bio-Seal Group | Experimental | Bio-Seal Plug Implanted |
|
| Control Group | No Intervention | Control group with no intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bio-Seal Plug | Device | Deployment of the Bio-Seal plug in needle track |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence Rate of Treatment Success | Treatment success was defined as the absence of a pneumothorax at each of the three follow-up time periods (0-60 minutes, 24 hours and 30 days). | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Chest Tube Placement | A chest tube is the definitive initial treatment of a pneumothorax. | 30 days |
| Time to Ambulation | 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rui Avelar, MD | Angiotech Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scottsdale Medical Imaging | Scottsdale | Arizona | 85258 | United States | ||
| St. Josephs Radiology Limited |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bio-Seal Group | Bio-Seal Plug Implanted |
| FG001 | Control Group | Control group with no intervention |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Incidence of Hospital Admissions for Pneumothorax | 30 day |
| Incidence of Adverse Events Related to the Procedure and Device Effects | Anticipated, device-related adverse events that were defined in the original protocol. | 30 Day |
| Number of Participants With Additional Chest X-rays Needed | 30 day |
| Participants Discharged Beyond Hospital's Standard of Care | Current standard of care for hospital discharge varies. Some institutions allow the patient to be discharged after a 3 hour wait. Others allow discharge after an x-ray indicates no pneumothorax. Since this study was randomized with control patients, the time to discharge beyond the hospital's standard of care was recorded to see if a trend for later discharge was apparent. This measure indicates the number of participants who were discharged later than their hospital's standard of care. | 30-day |
| Incidence of Adverse Events | Any treatment emergent adverse events (not considered device related by the investigators). | 30 days |
| Tuscon |
| Arizona |
| 85711 |
| United States |
| UCLA School of Medicine | Los Angeles | California | 90095 | United States |
| Univerisity of California, San Diego | San Diego | California | 92103 | United States |
| Stanford University Medical Center | Stanford | California | 94305 | United States |
| Vascular and Interventional Radiology | New Haven | Connecticut | 208042 | United States |
| Morton Plant Mease Health Care | Clearwater | Florida | 33756 | United States |
| Florida Research Network | Gainesville | Florida | 32605 | United States |
| UMass Memorial Medical Center | Worcester | Massachusetts | 01655 | United States |
| St. Louis Medical Center | St Louis | Missouri | 63110 | United States |
| Univeristy of Cincinnati Medical Center | Cincinnati | Ohio | 45287 | United States |
| St Lukes Hospital | Bethlehem | Pennsylvania | 18015 | United States |
| Memorial Medical Center | Johnstown | Pennsylvania | 15905 | United States |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | United States |
| Baptist Memorial Hospital | Memphis | Tennessee | 38120 | United States |
| University of Texas/MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
| Evergreen Healthcare Diagnostic Imaging | Kirkland | Washington | 98034 | United States |
| Sacred Heart Medical Center & Heart Institute of Spokane | Spokane | Washington | 99204 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bio-Seal Group | Bio-Seal Plug Implanted |
| BG001 | Control Group | Control group with no intervention |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| History of Smoking | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence Rate of Treatment Success | Treatment success was defined as the absence of a pneumothorax at each of the three follow-up time periods (0-60 minutes, 24 hours and 30 days). | Per Protocol Population | Posted | Number | participants | 30 days |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Incidence of Chest Tube Placement | A chest tube is the definitive initial treatment of a pneumothorax. | Intent to treat Population | Posted | Number | participants | 30 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Time to Ambulation | Intent to Treat Population | Posted | Mean | Standard Deviation | Hours | 30 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Incidence of Hospital Admissions for Pneumothorax | Intent to treat Population | Posted | Number | participants | 30 day |
|
| |||||||||||||||||||||||||||||||
| Secondary | Incidence of Adverse Events Related to the Procedure and Device Effects | Anticipated, device-related adverse events that were defined in the original protocol. | Intent to Treat Patients | Posted | Number | participants | 30 Day |
|
| ||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Additional Chest X-rays Needed | Intent to Treat Population | Posted | Number | participants | 30 day |
|
| |||||||||||||||||||||||||||||||
| Secondary | Participants Discharged Beyond Hospital's Standard of Care | Current standard of care for hospital discharge varies. Some institutions allow the patient to be discharged after a 3 hour wait. Others allow discharge after an x-ray indicates no pneumothorax. Since this study was randomized with control patients, the time to discharge beyond the hospital's standard of care was recorded to see if a trend for later discharge was apparent. This measure indicates the number of participants who were discharged later than their hospital's standard of care. | Intent to Treat Population | Posted | Number | participants | 30-day |
|
| ||||||||||||||||||||||||||||||
| Secondary | Incidence of Adverse Events | Any treatment emergent adverse events (not considered device related by the investigators). | Intent to Treat Population | Posted | Number | participants | 30 days |
|
|
30 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bio-Seal Group | Bio-Seal Plug Implanted | 1 | 170 | 60 | 170 | ||
| EG001 | Control Group | Control group with no intervention | 2 | 169 | 90 | 169 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| PULMONARY HEMORRHAGE | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| SYNCOPE | Cardiac disorders | MedDRA (9.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| NAUSEA | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| STOMATITIS | General disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ASTHENIA | General disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ADVERSE DRUG REACTION | General disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ATRIAL FIBRILLATION | Cardiac disorders | MedDRA (9.1) | Systematic Assessment |
| |
| CARDIAC FAILURE CONGESTIVE | Cardiac disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PANCYTOPENIA | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| CHEST PAIN | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PYREXIA | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ENERGY INCREASED | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| INFUSION SITE PAIN | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PUNCTURE SITE PAIN | Blood and lymphatic system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| FALL | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
| |
| CLAVICLE FRACTURE | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
| |
| HAEMOTHORAX | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
| |
| INCISION SITE COMPLICATION | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
| |
| PNEUMOTHORAX TRAUMATIC | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA (9.1) | Systematic Assessment |
| |
| URINARY TRACT INFECTION | Infections and infestations | MedDRA (9.1) | Systematic Assessment |
| |
| VULVOVAGINAL MYCOTIC INFECTION | Infections and infestations | MedDRA (9.1) | Systematic Assessment |
| |
| LUNG NEOPLASM | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (9.1) | Systematic Assessment |
| |
| MALIGNANT NEOPLASM PROGRESSION | Pregnancy, puerperium and perinatal conditions | MedDRA (9.1) | Systematic Assessment |
| |
| MALIGNANT PLEURAL EFFUSION | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (9.1) | Systematic Assessment |
| |
| NEOPLASM MALIGNANT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (9.1) | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA (9.1) | Systematic Assessment |
| |
| MUSCULOSKELETAL PAIN | Musculoskeletal and connective tissue disorders | MedDRA (9.1) | Systematic Assessment |
| |
| DEHYDRATION | Metabolism and nutrition disorders | MedDRA (9.1) | Systematic Assessment |
| |
| HYPONATRAEMIA | Metabolism and nutrition disorders | MedDRA (9.1) | Systematic Assessment |
| |
| CACHEXIA | Metabolism and nutrition disorders | MedDRA (9.1) | Systematic Assessment |
| |
| WEIGHT DECREASED | Investigations | MedDRA (9.1) | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| COUGH | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| DYSPNOEA EXERTIONAL | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| SYNCOPE | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
| |
| MENTAL STATUS CHANGES | Psychiatric disorders | MedDRA (9.1) | Systematic Assessment |
| |
| CONFUSIONAL STATE | Psychiatric disorders | MedDRA (9.1) | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA (9.1) | Systematic Assessment |
| |
| RENAL FAILURE ACUTE | Renal and urinary disorders | MedDRA (9.1) | Systematic Assessment |
| |
| URINARY RETENTION | Renal and urinary disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PULMONARY HAEMORRHAGE | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| EPISTAXIS | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PNEUMOTHORAX | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| HYPOXIA | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PLEURAL EFFUSION | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PULMONARY GRANULOMA | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| |
| RASH | Skin and subcutaneous tissue disorders | MedDRA (9.1) | Systematic Assessment |
| |
| PRURITUS | Skin and subcutaneous tissue disorders | MedDRA (9.1) | Systematic Assessment |
| |
| SUPERIOR VENA CAVAL OCCLUSION | Vascular disorders | MedDRA (9.1) | Systematic Assessment |
| |
| Allergic reaction to anesthesia/drugs | Immune system disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Bleeding at puncture site | Blood and lymphatic system disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Emphysema (subcutaneous) | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Hemoptysis | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Pleural fluid | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Chest pain with pneumothorax | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Chest pain without pneumothorax | Cardiac disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Puncture site bruising | Injury, poisoning and procedural complications | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Fatigue | General disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Coughing with Blood | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
| Altered lung function | Respiratory, thoracic and mediastinal disorders | Protocol | Systematic Assessment | Anticipated Adverse Device Effect |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Thomas Doyle | Angiotech | 352.338.0440 | tdoyle@angio.com |
| ID | Term |
|---|---|
| D011030 | Pneumothorax |
| ID | Term |
|---|---|
| D010995 | Pleural Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| Male |
|
| No |
|
|
|
|
|
|
|
|